Otilonium Bromide: Precision Antimuscarinic Agent for Neuroscience and Smooth Muscle Research

Executive Summary: Otilonium Bromide (SKU B1607, APExBIO) is a quaternary ammonium antimuscarinic agent with high purity (≥98%), optimized for in vitro neuroscience and smooth muscle research (product page). It functions as a potent acetylcholine receptor (AChR) inhibitor, modulating cholinergic signaling pathways in cellular models. Otilonium Bromide exhibits excellent solubility in DMSO (≥28.18 mg/mL), water (≥55.8 mg/mL), and ethanol (≥91 mg/mL), and is supplied as a powder or 10 mM DMSO solution. Its primary research applications include muscarinic receptor inhibition assays, gastrointestinal motility disorder models, and antispasmodic pharmacology (related article). Storage at -20°C is recommended for compound integrity. These features make Otilonium Bromide a critical reagent for reproducible receptor studies and advanced translational workflows (Vijayan & Gourinath, 2021).

Biological Rationale

Cholinergic signaling, mediated by acetylcholine, is fundamental in both the central and peripheral nervous systems. Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled receptors present in neuronal and smooth muscle tissues [DOI]. Dysregulation of cholinergic pathways contributes to neurological diseases, gastrointestinal motility disorders, and parasympathetic dysfunction. Selective pharmacological inhibition of mAChRs enables researchers to dissect these pathways with precision. Otilonium Bromide, as a quaternary ammonium compound, provides a reliable tool for modulating muscarinic signaling in vitro. This supports disease modeling, pathway elucidation, and screening of antispasmodic agents in controlled experimental systems.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide acts as a competitive antagonist at muscarinic acetylcholine receptors (mAChRs), specifically blocking receptor-mediated responses to acetylcholine. The compound inhibits signal transduction by binding to the orthosteric site of the mAChR, preventing receptor activation and downstream effects (see related analysis). As a quaternary ammonium agent, Otilonium Bromide displays enhanced selectivity for peripheral mAChRs and limited central nervous system penetration. Its action leads to reduced smooth muscle contractility and altered neurotransmitter release in experimental models. This mechanism supports its use in research on gastrointestinal motility, neuromuscular junctions, and cholinergic synaptic transmission.

Evidence & Benchmarks

• Otilonium Bromide demonstrates ≥98% chemical purity by HPLC under standard QC protocols (APExBIO).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at 25°C (APExBIO).
• In vitro assays confirm potent inhibition of muscarinic receptor-mediated smooth muscle contraction in rat colon tissue (IC₅₀ typically sub-micromolar) (Vijayan & Gourinath, 2021).
• Otilonium Bromide is stable for long-term storage at -20°C and maintains activity in solution for short-term assays (APExBIO).
• Preclinical models show reduced gastrointestinal motility and muscle spasm upon AChR inhibition using Otilonium Bromide (Vijayan & Gourinath, 2021).

Applications, Limits & Misconceptions

Otilonium Bromide is employed in:

• Cholinergic signaling pathway research and receptor binding studies.
• In vitro muscarinic receptor inhibition assays in neuroscience and gastrointestinal models.
• Pharmacological screening of antispasmodic agents.
• Modeling of gastrointestinal motility disorders, such as irritable bowel syndrome (IBS).

For detailed cell assay optimization, see this internal guide, which focuses on troubleshooting and comparative data; this article extends those findings by providing mechanism-based context and critical benchmarks.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not suitable for in vivo CNS studies due to limited blood-brain barrier penetration.
• It should not be used as a therapeutic agent in humans or animals; for research use only (RUO).
• Loss of activity may occur if aqueous solutions are stored long-term (use fresh solutions for each experiment).
• Does not inhibit nicotinic acetylcholine receptors (nAChRs), only muscarinic subtypes.
• Not effective as a broad-spectrum antiviral or anti-inflammatory without specific pathway validation.

For a strategic perspective on competitive and translational applications, see this analysis; our review clarifies the mechanistic basis and experimental limits of Otilonium Bromide for advanced research workflows.

Workflow Integration & Parameters

• Preparation: Otilonium Bromide is supplied as a solid or 10 mM DMSO solution; dilute to desired working concentration using sterile buffer or media.
• Stock Solution Stability: Store solid at -20°C; aliquot and avoid repeated freeze-thaw cycles. DMSO stock solutions are stable for up to 1 month at -20°C.
• In Vitro Assays: Typical working concentration ranges from 0.1–10 μM in cell-based or tissue assays. Confirm solubility and absence of precipitation before use.
• Controls: Include vehicle controls (DMSO ≤0.1%) to control for solvent effects.
• Disposal: Handle as a laboratory chemical; follow institutional safety and environmental protocols.

The Otilonium Bromide B1607 kit from APExBIO provides high consistency and batch-to-batch reproducibility for experimental workflows. For protocol design and advanced troubleshooting, consult both this article and this protocol guide, which offers hands-on strategies; this article updates those recommendations with the latest benchmarks and mechanistic context.

Conclusion & Outlook

Otilonium Bromide remains a foundational tool for cholinergic pathway research and smooth muscle pharmacology. Its high purity, robust antimuscarinic activity, and superior solubility empower researchers to design reproducible, high-impact experiments in neuroscience and gastrointestinal motility models. Limitations include peripheral selectivity and research-only designation; future studies may expand its applications through combination with other pathway modulators. For comprehensive technical details and ordering information, refer to the APExBIO Otilonium Bromide product page.